Niagen Bioscience is expanding Tru Niagen into GNC and Sam’s Club, placing its nicotinamide riboside supplements in nearly 300 retail locations across 44 states as well as both retailers’ online stores.
The launch is a meaningful commercial milestone for the company and for the broader longevity market. NAD-boosting products are moving from specialist websites and wellness clinics into mainstream retail. The scientific milestone is more limited: nicotinamide riboside reliably raises NAD levels, but human trials have not shown that it slows aging or consistently improves clinical outcomes.
Company development at a glance
Retail expansion: Nearly 300 GNC and Sam’s Club locations across 44 states, plus online sales.
Products: GNC is carrying Tru Niagen 300 mg and Tru Niagen Beauty. Sam’s Club is carrying a 120-count version of Tru Niagen 300 mg.
Company: Niagen Bioscience, formerly ChromaDex, trades on Nasdaq under the ticker NAGE.
2025 performance: The company reported $129.4 million in total net sales, including $97.7 million from Tru Niagen, and $17.4 million in net income.
Evidence level: Strong evidence that oral nicotinamide riboside raises blood NAD. Inconclusive evidence for anti-aging, healthspan or broad wellness benefits.
Why the retail move matters
GNC provides a national specialty-supplement channel, while Sam’s Club offers large-format retail and access to a broad membership base. The two placements give Niagen different customer segments and product formats.
For the company, physical retail can reduce reliance on direct-to-consumer advertising and online customer acquisition. It can also increase repeat purchasing and make the brand more visible to consumers who may not actively search for longevity products.
The expansion follows strong recent growth. Niagen Bioscience reported that 2025 net sales rose 30 percent and Tru Niagen sales rose 27 percent. The company ended the year with positive operating cash flow, $64.8 million in cash and no outstanding borrowings.
Those figures make the retail rollout more than an experiment by a cash-constrained supplement startup. Niagen is using a growing and profitable consumer business to expand distribution and invest in new products and pharmaceutical applications.
What nicotinamide riboside does
Nicotinamide riboside, or NR, is a form of vitamin B3 that the body can use to make nicotinamide adenine dinucleotide. NAD participates in energy metabolism, cellular signaling and DNA repair. Levels can decline with age in some tissues, which has made restoration an attractive target in aging research.
Human trials consistently show that oral NR can increase NAD-related metabolites in blood. That biochemical effect is real.
The unresolved question is whether increasing blood NAD produces a meaningful health benefit. Trials have tested NR in metabolic disease, cardiovascular risk, neurological conditions, exercise and long COVID. Results have generally been small, inconsistent or limited to exploratory endpoints.
A critical review of the first 25 published human studies concluded that oral NR produced few clinically relevant effects and that some reports overstated the importance of positive findings. A more recent systematic review similarly found clear biological activity but inconclusive clinical effectiveness for anti-aging and wellness.
The gap between a biomarker and a benefit
The retail announcement says Tru Niagen is clinically shown to increase and sustain NAD levels. That statement is narrower than proving healthy aging.
Raising a molecule associated with aging does not establish that a supplement prevents disease, preserves function or extends life. The same distinction applies to cholesterol, inflammation and epigenetic clocks: a biomarker is useful only when its movement predicts an outcome that matters.
For NR, researchers still need larger randomized trials with prespecified clinical endpoints, longer follow-up and enough participants to identify who may benefit. The answer may differ by age, disease status, baseline NAD metabolism and dose.
The investment case
Niagen Bioscience has several assets that distinguish it from many supplement companies. It owns core intellectual property around nicotinamide riboside, sells a branded consumer product, supplies Niagen as an ingredient and is exploring pharmaceutical-grade applications.
The GNC and Sam’s Club launch may increase sales volume and reinforce the company’s category leadership. It may also expose the brand to pricing pressure, retailer concentration and the promotional cycles common in mass-market supplements.
Scientific credibility remains commercially important. If future trials show meaningful benefits in a defined population, the company could gain a stronger medical and pricing position. If clinical outcomes remain modest, the business may continue to grow primarily through consumer interest in cellular-health biomarkers rather than demonstrated healthspan improvement.
Investors should separate those two cases.
What consumers should know
Tru Niagen is a dietary supplement, not an approved treatment for aging. Its availability at a major retailer does not change the standard of evidence.
People considering NR should evaluate cost, dose, other medications and their reason for taking it. Anyone being treated for a medical condition should discuss supplements with a clinician. Consumers should also distinguish the established finding, higher NAD after supplementation, from broader claims about energy, recovery, cognition or lifespan.
The Lifespan Brief assessment
The retail expansion is important business news because it shows longevity supplements entering ordinary consumer channels at scale. Niagen Bioscience has a growing brand, defensible intellectual property and stronger financial performance than many companies in the category.
The evidence boundary remains clear. Tru Niagen can raise NAD. It has not been shown to slow human aging. The commercial story is moving into the mainstream while the healthspan story remains under clinical investigation.